{
    "clinical_study": {
        "@rank": "94103", 
        "acronym": "NEURO-XAR", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This is local prospective multicenter observational non-interventional local study. Primary\n      study objective is investigate and describe prescription pattern of neurologists in\n      secondary stroke or non-CNS (non-Central Nervous System) systemic embolism prevention in\n      patients with AF (Atrial fibrillation) and prior stroke or TIA (Transient Ischemic attack)\n      who treat with rivaroxaban at an initial visit and three follow-up visits."
        }, 
        "brief_title": "Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stroke,", 
            "Embolism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Embolism", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients \u2265 18 years old who start treatment with rivaroxaban\n\n          -  Non-valvular Atrial Fibrillation is documented in patients' file\n\n          -  Prior TIA/Stroke history\n\n          -  TIA - more than 72 hours after documented TIA\n\n          -  more than 2 weeks after non-hemorrhagic stroke\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Contraindications for use of Xarelto\u00ae in accordance with approved product label\n\n          -  Previous thromboprophylaxis treatment with anticoagulants prior toby reason of stroke\n             / TIA prevention\n\n          -  Any reasons of medical and non-medical character, which in the opinion of the\n             physician can hamper patient participation in NIS"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Male and female patients \u2265 18 years old with prior stroke or TIA history and who have\n        never taken anticoagulation treatment regarding AF before and meet criteria of inclusion\n        and exclusion."
            }
        }, 
        "enrollment": {
            "#text": "214", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925755", 
            "org_study_id": "16627", 
            "secondary_id": "XA2012-01RU"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients  with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg", 
            "intervention_name": "Rivaroxaban ( Xarelto, BAY59-7939)", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-interventional", 
            "Rivaroxaban", 
            "Prevention in prior stroke or TIA", 
            "Russian Federation"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many locations", 
                    "country": "Russian Federation"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Multicenter Observational Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time lag after prior stroke or TIA before Xarelto prescription;\nFrequency of switching/discontinuation of Xarelto treatment;\nTime to switching/discontinuation of Xarelto treatment;\nReasons of switching/discontinuation of Xarelto treatment (using formalized criteria list);\nIn case of change of treatment - drug, dose, duration of use", 
            "measure": "Prescription pattern of neurologists in secondary stroke or non-CNS systemic embolism prevention in patients with AF and prior stroke or TIA who treat with rivaroxaban", 
            "safety_issue": "No", 
            "time_frame": "up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925755"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "CHA2DS2 VASC - Stroke risk assessment scale; HAS BLED - Score for Major Bleeding Risk (in anticoagulation therapy)", 
                "measure": "Descriptive characteristics of patients after prior stroke/TIA in the need of secondary stroke prevention with Xarelto (gender, age, race, alcohol/smoking, BMI and BP abnormalities, CHA2DS2 VASC, HAS BLED, Rankin Score)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "Identify time of start of anticoagulation therapy immediately after event (stroke or TIA) for secondary prevention in real life practice", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "Describe AE characteristics (frequency, severity, relation to treatment, AE treatment, AE outcome)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}